Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $48.140 million which missed the analyst consensus estimate of $48.610 million by 0.97 percent. This is a 5.57 percent increase over sales of $45.602 million the same period last year.